酒精相关性肝病的倾向评分匹配分析

IF 2.1 Q2 MEDICINE, GENERAL & INTERNAL

Health Science Reports Pub Date : 2025-01-12 DOI:10.1002/hsr2.70257

Fangfang Duan, Shanshan Song, Hang Zhai, Yazhi Wang, Jun Cheng, Song Yang

{"title":"酒精相关性肝病的倾向评分匹配分析","authors":"Fangfang Duan, Shanshan Song, Hang Zhai, Yazhi Wang, Jun Cheng, Song Yang","doi":"10.1002/hsr2.70257","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objectives</h3>\n \n <p>This study aims to investigate the impact of comorbidity with chronic hepatitis B (CHB) on the survival rates and incidence of liver cancer in patients with alcohol-related liver disease (ARLD).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Patients with ARLD and those with ARLD co-morbid with CHB were included in this study and designated as the ARLD group and the ARLD + HBV group, respectively. Propensity score matching (PSM) was then employed to compare survival rates and liver cancer development between these two groups.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Among the 404 patients, 254 were in the ARLD group and 150 in the ARLD + HBV group. After propensity score matching, each group comprised 67 patients. Initially, the ARLD + HBV group exhibited lower 5-year survival rates compared to the ARLD group (51.3% vs. 70.1%, <i>p</i> < 0.001). However, PSM mitigated this difference, with survival rates now comparable (61.2% vs. 60.9%, <i>p</i> = 0.390). Notably, the ARLD + HBV group showed a higher incidence of liver-specific mortality after matching (32.6% vs. 6.2%, <i>p</i> = 0.018). Furthermore, although a higher proportion of patients in the ARLD + HBV group developed liver cancer post-matching, the difference was not statistically significant compared to the ARLD group (15.7% vs. 9.8%, <i>p</i> = 0.170).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Co-morbidity with CHB in ARLD patients elevates the risk of liver-related mortality.</p>\n </section>\n </div>","PeriodicalId":36518,"journal":{"name":"Health Science Reports","volume":"8 1","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11725528/pdf/","citationCount":"0","resultStr":"{\"title\":\"Propensity Score Matching Analysis for Alcohol-Related Liver Disease\",\"authors\":\"Fangfang Duan, Shanshan Song, Hang Zhai, Yazhi Wang, Jun Cheng, Song Yang\",\"doi\":\"10.1002/hsr2.70257\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Objectives</h3>\\n \\n <p>This study aims to investigate the impact of comorbidity with chronic hepatitis B (CHB) on the survival rates and incidence of liver cancer in patients with alcohol-related liver disease (ARLD).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Patients with ARLD and those with ARLD co-morbid with CHB were included in this study and designated as the ARLD group and the ARLD + HBV group, respectively. Propensity score matching (PSM) was then employed to compare survival rates and liver cancer development between these two groups.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Among the 404 patients, 254 were in the ARLD group and 150 in the ARLD + HBV group. After propensity score matching, each group comprised 67 patients. Initially, the ARLD + HBV group exhibited lower 5-year survival rates compared to the ARLD group (51.3% vs. 70.1%, <i>p</i> < 0.001). However, PSM mitigated this difference, with survival rates now comparable (61.2% vs. 60.9%, <i>p</i> = 0.390). Notably, the ARLD + HBV group showed a higher incidence of liver-specific mortality after matching (32.6% vs. 6.2%, <i>p</i> = 0.018). Furthermore, although a higher proportion of patients in the ARLD + HBV group developed liver cancer post-matching, the difference was not statistically significant compared to the ARLD group (15.7% vs. 9.8%, <i>p</i> = 0.170).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Co-morbidity with CHB in ARLD patients elevates the risk of liver-related mortality.</p>\\n </section>\\n </div>\",\"PeriodicalId\":36518,\"journal\":{\"name\":\"Health Science Reports\",\"volume\":\"8 1\",\"pages\":\"\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-01-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11725528/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Health Science Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/hsr2.70257\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Science Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hsr2.70257","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

目的：本研究旨在探讨慢性乙型肝炎（CHB）合并症对酒精相关性肝病（ARLD）患者生存率和肝癌发病率的影响。方法：将ARLD合并慢性乙型肝炎患者和ARLD合并慢性乙型肝炎患者纳入本研究，分别分为ARLD组和ARLD + HBV组。然后采用倾向评分匹配（PSM）来比较两组之间的生存率和肝癌发展情况。结果：404例患者中，ARLD组254例，ARLD + HBV组150例。倾向评分匹配后，每组67例。最初，与ARLD组相比，ARLD + HBV组的5年生存率较低（51.3%对70.1%,p p = 0.390）。值得注意的是，ARLD + HBV组匹配后肝脏特异性死亡率发生率更高（32.6% vs. 6.2%, p = 0.018）。此外，虽然ARLD + HBV组患者配型后发生肝癌的比例较高，但与ARLD组相比差异无统计学意义（15.7% vs. 9.8%, p = 0.170）。结论：ARLD患者合并CHB可增加肝脏相关死亡风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Propensity Score Matching Analysis for Alcohol-Related Liver Disease

查看原文本刊更多论文

Propensity Score Matching Analysis for Alcohol-Related Liver Disease

Objectives

This study aims to investigate the impact of comorbidity with chronic hepatitis B (CHB) on the survival rates and incidence of liver cancer in patients with alcohol-related liver disease (ARLD).

Methods

Patients with ARLD and those with ARLD co-morbid with CHB were included in this study and designated as the ARLD group and the ARLD + HBV group, respectively. Propensity score matching (PSM) was then employed to compare survival rates and liver cancer development between these two groups.

Results

Among the 404 patients, 254 were in the ARLD group and 150 in the ARLD + HBV group. After propensity score matching, each group comprised 67 patients. Initially, the ARLD + HBV group exhibited lower 5-year survival rates compared to the ARLD group (51.3% vs. 70.1%, p < 0.001). However, PSM mitigated this difference, with survival rates now comparable (61.2% vs. 60.9%, p = 0.390). Notably, the ARLD + HBV group showed a higher incidence of liver-specific mortality after matching (32.6% vs. 6.2%, p = 0.018). Furthermore, although a higher proportion of patients in the ARLD + HBV group developed liver cancer post-matching, the difference was not statistically significant compared to the ARLD group (15.7% vs. 9.8%, p = 0.170).